Eosinophilic myeloid disorders

Seminars in Hematology

Volumn 49, Issue 2, 2012, Pages 120-127

  Noel, Pierre ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; CORTICOSTEROID; DASATINIB; FIP1L1 PDGFRA ONCOPROTEIN; HYDROXYUREA; IMATINIB; MEPOLIZUMAB; MIDOSTAURIN; NILOTINIB; ONCOPROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RESLIZUMAB; SORAFENIB; UNCLASSIFIED DRUG;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TUMOR; CARDIOMYOPATHY; CHRONIC EOSINOPHILIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DISEASE CLASSIFICATION; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; EOSINOPHILIC MYELOID DISORDER; ETV6 PDGFRA FUSION GENE; FGFR1 GENE; FIP1L1 PDGFRA FUSION GENE; GENE; GENE MUTATION; HEMATOLOGIC DISEASE; HUMAN; HYPEREOSINOPHILIC SYNDROME; LYMPHOMA; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA GENE; PLATELET DERIVED GROWTH FACTOR RECEPTOR BETA GENE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SYSTEMIC MASTOCYTOSIS;

ANIMALS; EOSINOPHILIA; EOSINOPHILS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MYELOPROLIFERATIVE DISORDERS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; WORLD HEALTH ORGANIZATION;

EID: 84858779837     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2012.01.008     Document Type: Article

References (61)

1. Cools J., DeAngelo D.J., Gotlib J., et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003, 348:1201-1214.
2. Reiter A., Walz C., Cross N.C. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 2007, 8:205-216.
3. Reiter A., Walz C., Watmore A., et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res 2005, 65:2662-2667.
4. Vu HA X.P., Masuda M., et al. FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation. Leukemia 2006, 20:1414-1421.
5. Walz C., Erben P., Ritter M., et al. Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood 2011, 118:2239-2242.
6. Pardanani A., Ketterling R.P., Brockman S.R., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003, 102:3093-3096.
7. Erben P., Gosenca D., Muller M.C., et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010, 95:738-744.
8. Klion A.D., Bochner B.S., Gleich G.J., et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006, 117:1292-1302.
9. Simon H.U., Rothenberg M.E., Bochner B.S., et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010, 126:45-49.
10. Bain BJ G.D., Horny H.P., et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008, 68-73. IARC Press, Lyon, France. S. Swerdlow, N.L. Harris, H. Stein, E.S. Jaffe, J. Theile, J.W. Vardiman (Eds.).
11. Bain BJ G.D., Horny H.P., et al. Chronic eosinophilic leukaemia, not otherwise specified. World Health Organization classification of tumours. Pathology and genetics of tumours of the haematopoietic and lymphoid tissues 2008, 51-53. IARC Press, Lyon, France. S. Swerdlow, N.L. Harris, H. Stein, E.S. Jaffe, J. Theile, J.W. Vardiman (Eds.).
12. Fink S.R., Belongie K.J., Paternoster S.F., et al. Validation of a new three-color fluorescence in situ hybridization (FISH) method to detect CHIC2 deletion, FIP1L1/PDGFRA fusion and PDGFRA translocations. Leuk Res 2009, 33:843-846.
13. Score J., Curtis C., Waghorn K., et al. Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia. Leukemia 2006, 20:827-832.
14. Metzgeroth G., Walz C., Score J., et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007, 21:1183-1188.
15. Elling C., Erben P., Walz C., et al. Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease. Blood 2011, 117:2935-2943.
16. Gotlib J., Cools J. Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias. Leukemia 2008, 22:1999-2010.
17. Kleinfeldt T., Nienaber C.A., Kische S., et al. Cardiac manifestation of the hypereosinophilic syndrome: new insights. Clin Res Cardiol 2010, 99:419-427.
18. Dulohery M.M., Patel R.R., Schneider F., Ryu J.H. Lung involvement in hypereosinophilic syndromes. Respir Med 2011, 105:114-121.
19. Burgstaller S., Kreil S., Waghorn K., et al. The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus. Leukemia 2007, 21:2428-2432.
20. Vandenberghe P., Wlodarska I., Michaux L., et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004, 18:734-742.
21. Klion A.D., Noel P., Akin C., et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003, 101:4660-4666.
22. Ogbogu P.U., Bochner B.S., Butterfield J.H., et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009, 124:1319-1325.
23. Pitini V., Arrigo C., Azzarello D., et al. Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes. Blood 2003, 102:3456-3457.
24. Sato Y., Taniguchi R., Yamada T., et al. Measurement of serum concentrations of cardiac troponin T in patients with hypereosinophilic syndrome: a sensitive non-invasive marker of cardiac disorder. Intern Med 2000, 39:350.
25. Schaller J.L., Burkland G.A. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med 2001, 3:9.
26. Gleich G.J., Leiferman K.M., Pardanani A., Tefferi A., Butterfield J.H. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet 2002, 359:1577-1578.
27. Ault P., Cortes J., Koller C., Kaled E.S., Kantarjian H. Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res 2002, 26:881-884.
28. Klion A.D., Robyn J., Akin C., et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004, 103:473-478.
29. Roumiantsev S., Shah N.P., Gorre M.E., et al. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 2002, 99:10700-10705.
30. Helbig G., Stella-Holowiecka B., Majewski M., et al. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients. Br J Haematol 2008, 141:200-204.
31. Jovanovic J.V., Score J., Waghorn K., et al. Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood 2007, 109:4635-4640.
32. Klion A.D., Robyn J., Maric I., et al. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Blood 2007, 110:3552-3556.
33. Baccarani M., Cilloni D., Rondoni M., et al. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica 2007, 92:1173-1179.
34. Imagawa J., Harada Y., Yoshida T., et al. [Successful treatment with low-dose dasatinib in a patient with chronic eosinophilic leukemia intolerant to imatinib]. Rinsho Ketsueki 2011, 52:546-550.
35. Tabouret E., Charbonnier A., Mozziconacci M.J., Ivanov V. Low-dose nilotinib can maintain complete molecular remissions in FIP1L1/PDGFRA-positive hypereosinophilic syndrome. Leuk Res 2011, 35:136.
36. Simon D., Salemi S., Yousefi S., Simon H.U. Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia. J Allergy Clin Immunol 2008, 121:1054-1056.
37. von Bubnoff N., Gorantla S.P., Engh R.A., et al. The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro. Oncogene 2011, 30:933-943.
38. Metzgeroth G., Erben P., Martin H., et al. Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation. Leukemia 2012, 26:162-164.
39. Lierman E., Michaux L., Beullens E., et al. FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib. Leukemia 2009, 23:845-851.
40. Nishioka C., Ikezoe T., Yang J., Yokoyama A. Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene. Leukemia 2010, 24:1631-1640.
41. Halaburda K., Prejzner W., Szatkowski D., Limon J., Hellmann A. Allogeneic bone marrow transplantation for hypereosinophilic syndrome: long-term follow-up with eradication of FIP1L1-PDGFRA fusion transcript. Bone Marrow Transplant 2006, 38:319-320.
42. Juvonen E., Volin L., Koponen A., Ruutu T. Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome. Bone Marrow Transplant 2002, 29:457-458.
43. Ueno N.T., Anagnostopoulos A., Rondon G., et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol 2002, 119:131-134.
44. Pardanani A., Brockman S.R., Paternoster S.F., et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004, 104:3038-3045.
45. Schoffski P., Ganser A., Pascheberg U., Busche G., Gaede B., Hertenstein B. Complete haematological and cytogenetic response to interferon alpha-2a of a myeloproliferative disorder with eosinophilia associated with a unique t(4;7) aberration. Ann Hematol 2000, 79:95-98.
46. Bohm A., Fodinger M., Wimazal F., et al. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol 2007, 120:192-199.
47. Horny H.P., Akin C., Metcalfe D.D., et al. Mastocytosis (mast cell disease). World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues 2008, 51:3. IARC Press, Lyon, France. S. Swerdlow, N.L. Harris, H. Stein, E.S. Jaffe, J. Theile, J.W. Vardiman (Eds.).
48. Maric I., Robyn J., Metcalfe D.D., et al. KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol 2007, 120:680-687.
49. Golub T.R., Barker G.F., Lovett M., Gilliland D.G. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994, 77:307-316.
50. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002, 347:481-487.
51. Steer E.J., Cross N.C. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta. Acta Haematol 2002, 107:113-122.
52. Carroll M., Ohno-Jones S., Tamura S., et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947-4952.
53. Nand R., Bryke C., Kroft S.H., Divgi A., Bredeson C., Atallah E. Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leuk Res 2009, 33:1144-1146.
54. Aguiar R.C., Macdonald D., Mason P.J., Cross N.C., Goldman J.M. Myeloproliferative disorder associated with 8p11 translocations. Blood 1995, 86:834-835.
55. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum Pathol 2010, 41:461-476.
56. Popovici C., Zhang B., Gregoire M.J., et al. The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood 1999, 93:1381-1389.
57. Vizmanos J.L., Hernandez R., Vidal M.J., et al. Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases. Hematol J 2004, 5:534-537.
58. Chen J., Deangelo D.J., Kutok J.L., et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A 2004, 101:14479-14484.
59. Matsushima T., Handa H., Yokohama A., et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003, 101:3386-3390.
60. Wimazal F., Germing U., Kundi M., et al. Evaluation of the prognostic significance of eosinophilia and basophilia in a larger cohort of patients with myelodysplastic syndromes. Cancer 2010, 116:2372-2381.
61. Kiladjian JJ M.R., Hoffman R. The renaissance of interferon therapy for teh treatment of myeloid malignancies. Blood 2011, 117:4701-4715.